STOCK TITAN
  1. Home
  2. Sec-filings
  3. AMJB
  4. [424B3] JPMORGAN CHASE & CO Prospectus Filed Pursuant to Rule 424(b)(3)

JPMorgan notes amendment sets Initial Values and 70% Barrier (AMJB)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
424B3

Rhea-AI Filing Summary

JPMorgan Chase Financial Company LLC amends a pricing supplement for structured notes linked to the Lesser Performing of the Russell 2000® Futures Excess Return Index and the iShares® MSCI EAFE ETF due March 6, 2031, and specifies the Initial Value and Barrier Amount for each underlying. The Initial Value equals the closing value on the Pricing Date: 352.58 for the Index and $100.09 for the Fund. The Barrier Amount is 70.00% of each Initial Value: 246.806 for the Index and $70.063 for the Fund. The amendment references related product and prospectus materials and lists CUSIP 46660MB20.

Positive

  • None.

Negative

  • None.

Insights

Amendment fixes pricing inputs and barrier levels for the notes; terms are now explicit.

The amendment records the Initial Value and the Barrier Amount for each underlying: 352.58 (Index) and $100.09 (Fund) as Initial Values, with barriers at 70.00%.

These figures determine payoff triggers on maturity March 6, 2031. Cash‑flow treatment and other risk disclosures remain in the referenced supplements and prospectus materials; investors should consult those documents for distribution methods and full risk factors.

The amendment ties specific numeric pricing inputs to the Pricing Date and references governing prospectus documents.

It explicitly attaches the Initial Value definition to the Pricing Date and preserves the Barrier Amount formula as "70.00% of its Initial Value." The amendment reiterates investor risk disclosures and regulatory disclaimers.

Relevant supporting documents are listed via hyperlinks; any material investor questions about proceeds, distribution mechanics, or secondary resale should be answered by the prospectus and product supplement referenced.

Initial Value (Index) 352.58 closing value on the Pricing Date for the Russell 2000® Futures Excess Return Index
Initial Value (Fund) $100.09 closing value on the Pricing Date for the iShares® MSCI EAFE ETF
Barrier Amount (Index) 246.806 70.00% of the Index Initial Value
Barrier Amount (Fund) $70.063 70.00% of the Fund Initial Value
Maturity Date March 6, 2031 final maturity for the structured notes
CUSIP 46660MB20 identifier for the notes
Initial Value financial
"the closing value of that Underlying on the Pricing Date"
Barrier Amount financial
"70.00% of its Initial Value"
Pricing Date regulatory
"closing value of that Underlying on the Pricing Date"
Product supplement regulatory
"product supplement no. 4-I dated April 13, 2023"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
April 6, 2026 Registration Statement Nos. 333-270004 and 333-270004-01; Rule 424(b)(3)
Amendment no. 1 to the pricing supplement dated March 3, 2026 to product supplement no. 4-I dated April 13, 2023, underlying supplement no. 1-I dated
April 13, 2023, the prospectus and prospectus supplement, each dated April 13, 2023, and the prospectus addendum dated June 3, 2024
JPMorgan Chase Financial Company LLC
Structured Investments
Review Notes Linked to the Lesser Performing of the Russell
2000® Futures Excess Return Index and the iShares® MSCI
EAFE ETF due March 6, 2031
Fully and Unconditionally Guaranteed by JPMorgan Chase & Co.
Notwithstanding anything to the contrary set forth in the pricing supplement dated March 3, 2026, related to the notes referred to above
(the “pricing supplement”), the Initial Value and the Barrier Amount of each Underlying are as follows:
Initial Value: With respect to each Underlying, the closing value of that Underlying on the Pricing Date, which was 352.58 for the Index
and $100.09 for the Fund
Barrier Amount: With respect to each Underlying, 70.00% of its Initial Value, which is 246.806 for the Index and $70.063 for the Fund
CUSIP: 46660MB20
Investing in the notes involves a number of risks. See “Risk Factors” beginning on page S-2 of the accompanying
prospectus supplement, Annex A to the accompanying prospectus addendum, “Risk Factors” beginning on page PS-11 of the
accompanying product supplement and “Selected Risk Considerations” beginning on page PS-5 of the pricing supplement.
Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of the
notes or passed upon the accuracy or the adequacy of this amendment, the pricing supplement or the accompanying product
supplement, underlying supplement, prospectus supplement, prospectus and prospectus addendum. Any representation to the
contrary is a criminal offense.
The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency and
are not obligations of, or guaranteed by, a bank.
You should read this amendment together with the pricing supplement and the related product supplement, underlying supplement,
prospectus supplement and prospectus and prospectus addendum, each of which can be accessed via the hyperlinks below. Please
also see “Additional Terms Specific to the Notes” in the pricing supplement.
● Pricing supplement dated March 3, 2026:
http://www.sec.gov/Archives/edgar/data/19617/000121390026024078/ea0280202-01_424b2.htm
● Product supplement no. 4-I dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000121390023029539/ea152803_424b2.pdf
● Underlying supplement no. 1-I dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000121390023029543/ea151873_424b2.pdf
● Prospectus supplement and prospectus, each dated April 13, 2023:
http://www.sec.gov/Archives/edgar/data/19617/000095010323005751/crt_dp192097-424b2.pdf
● Prospectus addendum dated June 3, 2024:
http://www.sec.gov/Archives/edgar/data/1665650/000095010324007599/dp211753_424b3.htm

Source: View Original Filing on SEC EDGAR